Haemonetics Details Executive Equity, Pension Adjustments in DEF 14A
Ticker: HAE · Form: DEF 14A · Filed: Jun 6, 2025 · CIK: 313143
| Field | Detail |
|---|---|
| Company | Haemonetics Corp (HAE) |
| Form Type | DEF 14A |
| Filed Date | Jun 6, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: Executive Compensation, DEF 14A, Corporate Governance, Equity Awards, Pension Adjustments, Medical Devices, Shareholder Meeting
Related Tickers: HAE
TL;DR
**HAE's DEF 14A is all about executive pay and equity, signaling a focus on long-term leadership incentives, so expect continued stability.**
AI Summary
Haemonetics Corp's DEF 14A filing for the fiscal year ending March 29, 2025, primarily details executive compensation and governance matters, rather than financial performance. The document outlines equity awards granted to Persons of the Company (PeoMember) for the period, including unvested awards granted during the year and in prior years, as well as vested awards. For instance, equity awards granted during the year and unvested for the period 2024-03-31 to 2025-03-29 are detailed, alongside similar data for previous fiscal years dating back to 2020. The filing also covers pension adjustments and service costs for the same periods, indicating ongoing employee benefit obligations. While specific revenue and net income figures are not present in this particular excerpt, the focus on compensation structures suggests a stable operational environment where executive incentives are a key component of strategic alignment. The strategic outlook, inferred from the compensation structure, emphasizes long-term equity performance and retention of key personnel.
Why It Matters
This DEF 14A filing provides crucial insights into Haemonetics' executive compensation philosophy, directly impacting investor confidence and governance perceptions. The structure of equity awards and pension adjustments can influence executive retention and motivation, which is vital for the company's long-term strategic execution in the competitive medical instruments sector. For employees, these details shed light on the company's commitment to benefits and long-term incentives. Customers and the broader market can infer stability and a focus on leadership continuity, which are important factors in a highly regulated industry like medical devices.
Risk Assessment
Risk Level: low — The filing is a routine DEF 14A, primarily detailing executive compensation and governance, not financial results or significant operational changes. The consistent reporting of equity awards and pension adjustments across multiple fiscal years (2020-2025) indicates standard corporate practices without immediate red flags for investors.
Analyst Insight
Investors should review the full DEF 14A to understand the specific performance metrics tied to executive compensation, as these often align with strategic goals. This information can help assess management's incentives and potential future performance drivers for Haemonetics.
Key Numbers
- 2025-03-29 — Conformed Period of Report End Date (Latest fiscal year-end covered by the filing)
- 2025-06-06 — Filed As Of Date (Date the DEF 14A was officially filed)
- 73 — Public Document Count (Number of documents included in the filing)
- 0000313143 — Central Index Key (CIK) (Unique identifier for Haemonetics Corp)
- 001-14041 — SEC File Number (Registration number for Haemonetics Corp)
Key Players & Entities
- HAEMONETICS CORP (company) — Filer of DEF 14A
- SEC (regulator) — Recipient of the DEF 14A filing
- Persons of the Company (person) — Recipients of equity awards and pension adjustments
- Bloomberg (company) — Financial news outlet
- Boston (company) — City of Haemonetics' business address
FAQ
What is the primary purpose of Haemonetics Corp's DEF 14A filing?
The primary purpose of Haemonetics Corp's DEF 14A filing is to provide information regarding executive compensation, including equity awards and pension adjustments, and other governance matters in preparation for its annual shareholder meeting.
What period does the Haemonetics DEF 14A filing cover for executive compensation?
The Haemonetics DEF 14A filing covers executive compensation data, including equity awards and pension adjustments, for fiscal years ranging from 2020-03-29 to 2025-03-29.
Does the Haemonetics DEF 14A filing include revenue figures?
No, this specific excerpt of the Haemonetics DEF 14A filing does not include revenue figures. It focuses on executive compensation, equity awards, and pension adjustments rather than financial performance metrics like revenue or net income.
What types of compensation are detailed for Haemonetics' executives in the DEF 14A?
The DEF 14A details equity awards, specifically unvested awards granted during the year and in prior years, as well as vested awards. It also covers pension adjustments and service costs for the Persons of the Company.
When was Haemonetics Corp's DEF 14A officially filed?
Haemonetics Corp's DEF 14A was officially filed on 2025-06-06, with the conformed period of report ending on 2025-03-29.
What is the significance of equity awards in Haemonetics' DEF 14A for investors?
For investors, the equity awards detailed in Haemonetics' DEF 14A are significant as they indicate how executive incentives are structured and aligned with long-term company performance, potentially influencing future stock performance and management retention.
Where is Haemonetics Corp's business address located?
Haemonetics Corp's business address is located at 125 Summer Street, Boston, MA 02110.
What is the Central Index Key (CIK) for Haemonetics Corp?
The Central Index Key (CIK) for Haemonetics Corp is 0000313143, which is a unique identifier used by the SEC.
Are there any immediate risks highlighted in this Haemonetics DEF 14A filing?
Based on the provided excerpt, there are no immediate risks highlighted in this Haemonetics DEF 14A filing. It primarily outlines routine executive compensation and governance information, suggesting a low risk level.
How does the DEF 14A filing reflect Haemonetics' approach to executive retention?
The DEF 14A filing reflects Haemonetics' approach to executive retention through its detailed disclosure of equity awards, both vested and unvested, and pension adjustments. These long-term incentives are designed to align executive interests with shareholder value and encourage continued service.
Industry Context
Haemonetics Corp operates within the surgical and medical instruments and apparatus industry (SIC 3841). This sector is characterized by innovation, regulatory scrutiny, and a focus on improving patient outcomes and healthcare efficiency. Key trends include the development of advanced medical devices, increasing demand for minimally invasive technologies, and the integration of digital solutions for data management and remote patient monitoring.
Regulatory Implications
As a medical device company, Haemonetics Corp is subject to stringent regulations from bodies like the FDA. Compliance with quality standards, manufacturing practices, and post-market surveillance is critical. Changes in healthcare policy or reimbursement rates can also impact the company's financial performance and market access.
What Investors Should Do
- Review executive compensation details for alignment with company performance.
- Monitor pension plan adjustments and service costs.
Key Dates
- 2025-03-29: Conformed Period of Report End Date — Marks the end of the fiscal year for which the DEF 14A filing provides information, primarily concerning executive compensation and governance.
- 2025-06-06: Filed As Of Date — Indicates the date Haemonetics Corp officially submitted this DEF 14A filing to the SEC.
- 2024-03-31: Previous Fiscal Year End — Represents the end of the prior fiscal year, used for comparative analysis of executive compensation and benefits.
- 2023-04-02: Fiscal Year End — Marks the end of the fiscal year prior to the most recent one, providing further historical data for compensation trends.
- 2022-04-03: Fiscal Year End — Provides historical data for executive compensation and benefits from two fiscal years prior.
- 2021-04-04: Fiscal Year End — Offers historical context for executive compensation and benefits from three fiscal years prior.
Glossary
- DEF 14A
- A proxy statement filing required by the SEC for publicly traded companies. It provides shareholders with information about matters to be voted on at an annual or special meeting, including executive compensation, director elections, and other corporate governance issues. (This document is the primary source of information for executive compensation, equity awards, and pension adjustments for Haemonetics Corp's Persons of the Company (PeoMember).)
- PeoMember
- Likely refers to 'Persons Excluded from Other Members' or a similar designation within the company's reporting structure, typically encompassing executive officers and directors. (This term specifies the group of individuals whose compensation, equity awards, and pension adjustments are detailed in the filing.)
- Equity Awards
- Grants of company stock, stock options, or other equity-based compensation given to employees, typically as part of their remuneration and to align their interests with shareholders. (The filing details various equity awards granted to executives, including unvested and vested awards, both granted during the year and in prior years, indicating a focus on long-term incentives.)
- Conformed Period of Report
- The period covered by the filing, usually the company's fiscal year. (In this case, it signifies the fiscal year ending March 29, 2025, for which executive compensation data is presented.)
- Pension Adjustments
- Changes to a company's defined benefit pension plan obligations, which can include service cost, interest cost, and actuarial gains or losses. (The filing includes data on pension adjustments and service costs for executive members, indicating ongoing management of retirement benefit obligations.)
- SIC Code 3841
- Standard Industrial Classification code for 'Surgical & Medical Instruments & Apparatus'. (Classifies Haemonetics Corp's primary business activity, providing context for its industry and market.)
Year-Over-Year Comparison
This DEF 14A filing focuses on executive compensation and governance for the fiscal year ending March 29, 2025. Specific financial performance metrics like revenue and net income are not detailed in this excerpt. Therefore, a direct comparison of financial metrics such as revenue growth or margin changes to the previous year's filing is not possible based on this document alone. The emphasis remains on the structure of executive incentives and employee benefits.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on June 6, 2025 by Persons of the Company regarding HAEMONETICS CORP (HAE).